Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations

Slide collection

215,701-215,730 of 319,975

filter-aware
01
Slide 1
The slide features both the Aeglea and Spyre Therapeutics logos, indicating a transition or merger context.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
02
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
03
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
04
Includes a footnote regarding a 1-for-25 reverse stock split.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
05
The slide uses a pipeline chart format to show the development status of seven different programs.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
06
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
07
The slide uses a donut chart to illustrate market growth from 2021 to 2028.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
08
The chart uses a visual metaphor of an arrow pointing from current standard of care (SOC) to a higher efficacy/convenience target.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem (Identify pain)1 hit
09
The slide uses a numbered list format to present strategic pillars.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)1 hit
10
The slide uses a visual representation of an antibody molecule with callouts to specific engineering improvements, supported by a scatter plot showing clinical precedent for half-life extension.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Aha Moment1 hit
11
Uses a visual metaphor of antibody combination to explain the therapeutic strategy.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Aha Moment1 hit
12
The slide uses a Venn diagram to represent the intersection of genetic targets and a bar chart to demonstrate the efficacy of patient selection.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Aha Moment1 hit
13
The slide uses a Gantt-style pipeline visualization to show progress of seven distinct programs.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Aha Moment1 hit
14
The slide uses a Gantt-style layout to show progress across Discovery, IND-Enabling, and Clinical stages.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Aha Moment1 hit
15
Includes a KOL quote and two charts: a bar chart for global sales and a line chart for market share.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Aha Moment1 hit
16
The chart uses a vertical axis to imply a safety spectrum (Safest to Riskiest) and a horizontal axis for efficacy (clinical remission %).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Aha Moment1 hit
17
The slide uses a checkmark/arrow matrix to highlight competitive differentiation.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Aha Moment1 hit
18
The slide uses a standard antibody diagram to annotate specific engineering improvements.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Aha Moment1 hit
19
Includes structural visualization of the epitope and two dose-response curves.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Aha Moment1 hit
20
The chart shows dose-response curves for three donors; the table summarizes the calculated EC50 values.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
21
The chart uses a log-linear scale for concentration over time to demonstrate the beta-elimination phase.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
22
The slide uses a bar chart to compare pharmacokinetic properties between a proprietary drug candidate (SPY001) and a competitor (Entyvio).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
23
Uses a visual timeline/comparison to contrast current standard of care with the proposed product.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
24
The slide uses a bar chart to show benchmark data alongside a specific exposure-response analysis for vedolizumab.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
12
Yatsen | Results Presentation Deck | 17 slidesYatsen | Results Presentation Deck | 17 slides · Yatsen Holding Limited
Conference presentation Investor relations Beat · Action1 hit
13
The slide explains the drivers behind the financial performance metrics.Yatsen | Results Presentation Deck | 17 slides · Yatsen Holding Limited
Conference presentation Investor relations Beat · Action1 hit
14
The chart shows a breakdown of R&D, G&A, S&M, and Fulfillment expenses.Yatsen | Results Presentation Deck | 17 slides · Yatsen Holding Limited
Conference presentation Investor relations Beat · Action1 hit
15
The slide provides a detailed breakdown of adjustments made to GAAP net income to arrive at non-GAAP figures, including share-based compensation, amortization, and investment revaluations.Yatsen | Results Presentation Deck | 17 slides · Yatsen Holding Limited
Conference presentation Investor relations Beat · Action1 hit
16
The chart displays two distinct metrics: a running balance (top row) and quarterly cashflow (bars).Yatsen | Results Presentation Deck | 17 slides · Yatsen Holding Limited
Conference presentation Investor relations Beat · Action1 hit
17
Yatsen | Results Presentation Deck | 17 slidesYatsen | Results Presentation Deck | 17 slides · Yatsen Holding Limited
Conference presentation Investor relations Beat · Action1 hit